Oct. 3 at 11:53 AM
H.C. Wainwright reiterated
$MAZE Buy/
$50
$VRTX $UNCY $OTSKY
HCW said in its note to investors: We continue to believe that the next wave of kidney disease innovation will be defined by therapies that can demonstrate clinically meaningful proteinuria reductions and supportive eGFR trends in genetically enriched populations, with regulatory acceptance of these measures as surrogate endpoints. Towards that, we think Maze's MZE829 is uniquely positioned as the leading APOL1 targeted therapy, directly aligned with the recent PARASOL initiative and Rosenberg et al.'s validation of proteinuria and slope as predictors of kidney failure.
With no approved therapies for APOL1 kidney disease and Vertex as the only major competitor, we believe Maze is undervalued at current levels, and that Phase 2 data in Q1 2026 could serve as the inflection point for accelerated approval narratives and a significant upside for the stock. We reiterate our Buy rating and our price target of
$50.
